Reveal and Ona partner on novel ADC for resistant cancers

Spanish biotech Reveal Genomics has formed a strategic partnership with oncology firm Ona Therapeutics to support the clinical development of ONA-255, a novel antibody-drug conjugate designed to target therapy-resistant tumor cells in advanced solid cancers.

The companies said the collaboration will focus on the ongoing Phase I/II trial of ONA-255, which is engineered to deliver a powerful drug payload to tumor cells that have adapted to evade standard treatments. Ona aims to use the therapy to treat a broad range of cancers, with a focus on resistant disease.

Reveal will lead molecular and genomic analysis during the trial, using its proprietary technologies to help define which patient populations could benefit from the treatment. The Barcelona-based company will analyze tumor and blood samples to identify biomarkers linked to response and resistance, as well as further understand the therapy’s mechanism of action.